Skip to Main Content

Paper Details

Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy.
Mol Cancer Res
10
2022
AKT, BRAF, BRAF V600E, ERK, JAK, MAPK, PI3K, RNA, SNF, STAT, SWI, Thyroid Carcinoma, V600E, advanced thyroid tumors, dedifferentiated thyroid cancer, mTOR, oncogenic PIK3CA, oncogenic PIK3CA mutation, patient, thyroid cancer, thyroid cancers, thyroid carcinomas, thyroid tumor, tumor, tumors, vemurafenib
Author NameAffiliation
Fengshen KuoMemorial Sloan Kettering Cancer Center
Fengshen KuoMemorial Sloan Kettering Cancer Center
Vladimir MakarovCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Vladimir MakarovCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Richard J WongMemorial Sloan Kettering Cancer Center
Eric J ShermanMemorial Sloan Kettering Cancer Center
Alan L HoMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
  • 1 - 13

Datasets

Release 1.2